Metabolon and the Harvard-Partners Center for Genetics and Genomics Announce Warfarin Dosing Diagnostic Development Collaboration

RESEARCH TRIANGLE PARK, N.C. & BOSTON--(BUSINESS WIRE)--Metabolon, Inc., the leader in metabolomics-driven biomarker discovery and analysis, and the Harvard-Partners Center for Genetics and Genomics (HPCGG), a collaborative program dedicated to promoting genetics and genomics in research and clinical medicine, announced today that they have signed an agreement to develop an improved diagnostic test for enabling a more accurate dosing of warfarin. Warfarin, a blood thinning agent prescribed extensively during the last 50 years, causes more than 700,000 adverse events per year due to improper dosing (JAMA 2006; 296).

Back to news